Interview with Israel Garcia Crespo, General Manager, Almirall Mexico
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Address: Periferico Sur 3325 Piso 1, Col. San Jeronimo Lidice, Mexico D.F.
,Mexico
Tel: +52 5 559 998 600
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company with headquarters in Spain, based on innovation and committed to health, and develops, manufactures and commercializes its own Research & Development driven licensed drugs, with the aim of improving health and welfare of people. Currently, our drugs are marketed in over 70 countries including the USA and Japan, either through our own subsidiaries or through marketing agreements with renowned pharmaceutical companies. Almirall has 11 subsidiaries in Europe, including Spain, Germany, Austria, Belgium, France, Italy, Poland, Portugal, United Kingdom, Ireland and Switzerland and Mexico. Almirall S.A. de C.V.- the company’s only Latin American presence- began operating in 2000 with the aim of consolidating the company’s international expansion and entering placing its main strategic products into the Mexican market specifically.
Almirall S.A. de C.V. currently has 9 innovative products in the Mexican market in fields ranging from Dermatology to Oncology, which provide solutions to Mexican society in improving their quality of life and health.
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for…
What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office…
Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies. In Mexico, approximately 15 percent of patients treated…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving…
David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to…
See our Cookie Privacy Policy Here
